HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert A Kratzke Selected Research

Eukaryotic Initiation Factor-4F (EIF4F)

1/2020Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.
1/2019Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer.
1/20184EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
8/2014Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
1/2013Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
3/2011Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert A Kratzke Research Topics

Disease

37Neoplasms (Cancer)
10/2020 - 02/2002
21Mesothelioma
01/2022 - 02/2002
21Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 03/2002
11Lung Neoplasms (Lung Cancer)
07/2020 - 11/2002
11Malignant Mesothelioma
01/2020 - 02/2002
6Leukemia
10/2015 - 03/2005
5Neoplasm Metastasis (Metastasis)
07/2006 - 03/2002
3Breast Neoplasms (Breast Cancer)
10/2020 - 04/2006
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2015 - 01/2005
2Vesicular Stomatitis
07/2020 - 10/2015
2Infections
11/2019 - 09/2017
2Pancreatic Neoplasms (Pancreatic Cancer)
10/2015 - 02/2008
2Adenocarcinoma
12/2011 - 11/2004
2Disease Progression
03/2010 - 03/2005
2Carcinogenesis
10/2004 - 11/2002
2Neoplasm Micrometastasis
09/2004 - 03/2002
1Virus Diseases (Viral Diseases)
01/2017
1Lymphoma (Lymphomas)
03/2011
1B-Cell Lymphoma (Lymphoma, B Cell)
03/2011
1Idiopathic Pulmonary Fibrosis
06/2009
1Chronic Obstructive Pulmonary Disease (COPD)
06/2009
1Glioma (Gliomas)
11/2008

Drug/Important Bio-Agent (IBA)

11Proteins (Proteins, Gene)FDA Link
01/2020 - 02/2002
6Eukaryotic Initiation Factor-4F (EIF4F)IBA
01/2020 - 03/2011
6GemcitabineFDA Link
01/2013 - 01/2005
4DNA (Deoxyribonucleic Acid)IBA
10/2015 - 11/2002
4Messenger RNA (mRNA)IBA
08/2014 - 03/2002
4ErbB Receptors (EGF Receptor)IBA
09/2013 - 03/2005
3Pemetrexed (MTA)FDA Link
01/2020 - 01/2013
3Carcinoembryonic AntigenIBA
08/2014 - 03/2002
3Pharmaceutical PreparationsIBA
08/2014 - 11/2002
3RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
12/2011 - 03/2002
24Ei-10IBA
01/2021 - 01/2020
2InterferonsIBA
07/2020 - 10/2015
2Eukaryotic Initiation Factor-4EIBA
06/2017 - 01/2013
2ProdrugsIBA
03/2015 - 08/2014
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
06/2012 - 02/2008
2Dasatinib (BMS 354825)FDA Link
04/2012 - 03/2010
2JNK Mitogen-Activated Protein KinasesIBA
02/2012 - 09/2007
2Cyclin-Dependent Kinase Inhibitor p16IBA
01/2010 - 11/2002
2CytidineIBA
04/2008 - 11/2002
25,6-dihydro-5-azacytidineIBA
04/2008 - 11/2002
2Tumor Suppressor Protein p14ARF (p14ARF)IBA
01/2008 - 02/2002
1Complement System Proteins (Complement)IBA
07/2020
1Antiviral Agents (Antivirals)IBA
07/2020
1Interferon Type IIBA
11/2019
1ruxolitinibIBA
11/2019
1OsteopontinIBA
01/2018
1VaccinesIBA
09/2017
1RNA Cap-Binding Proteins (Cap Binding Protein)IBA
06/2017
1Aminacrine (Aminoacridine)IBA
10/2015
1AcridinesIBA
10/2015
1Etoposide (VP 16)FDA LinkGeneric
10/2015
1PoisonsIBA
10/2015
114-O-phosphonooxymethyltriptolide disodium saltIBA
03/2015
1DiterpenesIBA
03/2015
1Saline SolutionIBA
03/2015
1triptolideIBA
03/2015
1Untranslated RNA (Noncoding RNA)IBA
01/2015
1Measles VaccineIBA
08/2014
1Guanosine Monophosphate (5' Guanylic Acid)IBA
08/2014
1MicroRNAs (MicroRNA)IBA
11/2013
1Tyrosine Kinase InhibitorsIBA
09/2013
1Topotecan (Hycamtin)FDA LinkGeneric
09/2013
1Biomarkers (Surrogate Marker)IBA
09/2013
1Bevacizumab (Avastin)FDA Link
09/2013
1Antisense OligonucleotidesIBA
01/2013
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
06/2012
1EnzymesIBA
12/2011
1CytokinesIBA
12/2011
1ImmunosorbentsIBA
12/2011
1Opioid Receptors (Opioid Receptor)IBA
12/2011
1Bromodeoxyuridine (BrdU)IBA
12/2011
1Morphine (MS Contin)FDA LinkGeneric
12/2011
1Epidermal Growth Factor (EGF)IBA
12/2011
1Calcium Channels (Calcium Channel)IBA
05/2011
1Flavin-Adenine Dinucleotide (FAD)IBA
05/2011
1Cyclin D2IBA
05/2011
1Ligases (Synthetase)IBA
05/2011
1Formaldehyde (Formol)FDA Link
03/2011
1Carrier Proteins (Binding Protein)IBA
03/2011
1ParaffinIBA
03/2011
1Peptide Initiation Factors (Initiation Factor)IBA
03/2011
1Cisplatin (Platino)FDA LinkGeneric
02/2010
1Thalidomide (Thalomid)FDA Link
08/2009
1Carboplatin (JM8)FDA LinkGeneric
08/2009
1Small Interfering RNA (siRNA)IBA
11/2008
1epidermal growth factor receptor VIIIIBA
11/2008
1Therapeutic UsesIBA
11/2008

Therapy/Procedure

22Therapeutics
01/2022 - 11/2004
6Oncolytic Virotherapy
11/2019 - 04/2013
3Injections
10/2015 - 08/2014
3Thoracotomy
12/2008 - 07/2006
1Immunotherapy
01/2017
1Aftercare (After-Treatment)
03/2015
1Salvage Therapy
09/2013
1Radiotherapy
01/2010
1Neoadjuvant Therapy
08/2009
1Lung Transplantation
06/2009
1Drug Therapy (Chemotherapy)
02/2008